Looks like Sanjay Lakhotia from Zenith gave a presentation at the BioJapan 2016 conference last month on October 12th. Here is the description for the seminar, which was part of the Embassy of Canada in Japan, 7th Canada Life Sciences Seminar "Opportunities in Canada - Forefront of Cancer Immunotherapy Development".

Clinical Development of a Novel Bromodomain Inhibitor for Solid Tumors: Epigenetic Modulation for Immuno-oncology Applications

Zenith is conducting Phase I study of a highly potent and selective bromodomain inhibitor, ZEN 3694 for prostate cancer. This seminar will focus on the interim data of the trial and the potential of ZEN3694.